Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04889495
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-30
First Post:
2021-05-12
Brief Title:
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Prospective Single-arm Open-label Non-interventional Multicenter Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer Metastatic Colorectal Cancer Metastatic Breast Cancer Advanced or Metastatic Kidney Cancer Cervical Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer or Glioblastoma Multiforme
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-arm open-label non-interventional multicenter post-marketing surveillance to assess the safety and effectiveness of ZirabevBevacizumab biosimilar in domestic patients with non-small cell lung cancer metastatic colorectal cancer metastatic breast cancer advanced or metastatic kidney cancer cervical cancer epithelial ovarian cancer fallopian tube cancer primary peritoneal cancer or glioblastoma multiforme
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None